Read our latest newsletters here and keep up to date with what we’ve been up to.
Isogenica have developed fully synthetic, in vitro plugandplay cassettebased approach to efficiently generate combinations of bi and trispecific VHH, exemplified in in vitro studies.
Tune in to hear Isogenica’s CSO Dr Bill Eldridge describe applications of naturally monovalent antibody domain structure combined to generate the next generation of multi-specific biologics.
Meet David Mead, Director of Business Development and Associate Director of Marketing, Dr Mandeep Sehmi at the BIO International Convention Digital 2021 June 10-11 & 14-18, to learn the latest developments of VHH single domain antibodies to tumour targets.
Listen to Senior Director of Antibody Discovery Dr Ed McGowan and his thorough review of the applications of VHH single domain antibodies in CAR-T and T cell engagers.
Isogenica has announced today that Jan-Olof Lundin, Non-Executive Chairman of the Board of Directors (the “Board”) will retire from the Board effective 31 December 2019.
Nature Communications publishes UMC Utrecht and Isogenica research on VHHmediated targeting of LRP5 and LRP6
Under a collaboration between Isogenica and scientists at the Oncode Institute and University Medical Center Utrecht, led by Professor Madelon Maurice, Isogenica’s fully synthetic, highly diverse LlamdA™ library was screened for Wnt pathway inhibitors using CIS Display, the company’s in vitro library selection system.